AbbVie Inc. (ABBV): Results of Operations and Financial Condition
AbbVie Inc. (ABBV) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE AbbVie Reports Second-Quarter 2026 Financial Results • Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0.17 Per Sha
How this was made
The 30-second read
Why it matters
The filing provides fresh, tradable inputs: Q2 EPS and revenue by portfolio, margin and expense ratios, and a revised 2026 adjusted EPS guidance range that incorporates acquisition-related dilution. It also adds deal terms (valuation and expected Q3 2026 close) that can drive forward expectations and risk premia.
Market read
Traders can reprice ABBV on the same-day guidance reset and acquisition dilution, while monitoring portfolio mix signals (immunology and neuroscience strength versus oncology and Humira softness).
What to watch
Investors may underweight the magnitude of acquired IPR&D and milestones expense impacts on GAAP/adjusted metrics, and overemphasize headline adjusted EPS without modeling deal economics into 2027+.
AbbVie Reports Second-Quarter 2026 Financial Results
Worldwide net revenues increased 10.2 percent on a reported basis, immunology and neuroscience both delivered double-digit reported growth, and adjusted diluted EPS increased 22.9 percent. Results were partly offset by declining Humira and Imbruvica sales, an operational decline in aesthetics, acquired IPR&D and milestones expense, and guidance dilution related to the proposed Apogee Therapeutics acquisition.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Worldwide net revenuesother | $16.990 billion | – | an increase of 10.2 percent on a reported basis, or 9.5 percent on an operational basis |
| Gross margin ratioGAAP | 74.7 percent | – | – |
| Adjusted gross margin rationon-GAAP | 84.7 percent | – | – |
| Selling, general and administrative expenseGAAP | 21.4 percent of net revenues | – | – |
| Adjusted selling, general and administrative expensenon-GAAP | 21.0 percent of net revenues | – | – |
| Research and development expenseGAAP | 13.8 percent of net revenues | – | – |
| Adjusted research and development expensenon-GAAP | 13.6 percent of net revenues | – | – |
| Acquired IPR&D and milestones expenseother | 1.7 percent of net revenues | – | – |
| Operating margin ratioGAAP | 37.9 percent | – | – |
| Adjusted operating margin rationon-GAAP | 48.3 percent | – | – |
| Net interest expenseGAAP | $679 million | – | – |
| Tax rateGAAP | 15.5 percent | – | – |
| Adjusted tax ratenon-GAAP | 14.7 percent | – | – |
| Diluted earnings per shareGAAP | $2.03 | – | an increase of 290.4 percent |
| Adjusted diluted earnings per sharenon-GAAP | $3.65 | – | an increase of 22.9 percent |
| Acquired IPR&D and milestones expense impact per shareother | $0.17 per share | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Immunology portfolioSkyrizi and Rinvoq each posted reported growth above 24 percent, while Humira declined. | $8.786 billion | – | an increase of 15.1 percent on a reported basis, or 14.6 percent on an operational basis |
| SkyriziGlobal net revenues increased. | $5.505 billion | – | an increase of 24.4 percent on a reported basis, or 24.0 percent on an operational basis |
| RinvoqGlobal net revenues increased. | $2.525 billion | – | an increase of 24.5 percent on a reported basis, or 23.7 percent on an operational basis |
| HumiraGlobal net revenues decreased. | $756 million | – | a decrease of 35.9 percent on a reported basis, or 36.1 percent on an operational basis |
| Neuroscience portfolioVraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev contributed to the portfolio. | $3.228 billion | – | an increase of 20.3 percent on a reported basis, or 19.8 percent on an operational basis |
| VraylarGlobal net revenues increased. | $1.071 billion | – | an increase of 18.9 percent |
| Botox TherapeuticGlobal net revenues increased. | $1.042 billion | – | an increase of 12.2 percent on a reported basis, or 11.6 percent on an operational basis |
| UbrelvyGlobal net revenues increased. | $392 million | – | an increase of 16.0 percent on a reported basis, or 15.9 percent on an operational basis |
| QuliptaGlobal net revenues increased. | $350 million | – | an increase of 30.9 percent on a reported basis, or 30.3 percent on an operational basis |
| VyalevGlobal net revenues were reported. | $256 million | – | – |
| Oncology portfolioVenclexta and Elahere growth was offset by an Imbruvica decline. | $1.650 billion | – | a decrease of 1.5 percent on a reported basis, or 2.4 percent on an operational basis |
| VenclextaGlobal net revenues increased. | $771 million | – | an increase of 11.6 percent on a reported basis, or 9.6 percent on an operational basis |
| ImbruvicaGlobal net revenues decreased. | $532 million | – | a decrease of 29.4 percent |
| ElahereGlobal net revenues increased. | $211 million | – | an increase of 33.1 percent on a reported basis, or 31.8 percent on an operational basis |
| Aesthetics portfolioBotox Cosmetic growth was offset in part by a Juvederm decline. | $1.282 billion | – | an increase of 0.3 percent on a reported basis, or a decrease of 0.9 percent on an operational basis |
| Botox CosmeticGlobal net revenues increased. | $728 million | – | an increase of 5.2 percent on a reported basis, or 3.4 percent on an operational basis |
| JuvedermGlobal net revenues decreased. | $245 million | – | a decrease of 6.0 percent on a reported basis, or 6.6 percent on an operational basis |
2026 outlook
- NoteAdjusted diluted EPS guidance range: $13.87 - $14.07
- NoteIncludes a $0.14 per Share Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics
- NoteIncludes an Unfavorable Impact of $0.58 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2026
What drove it
- Worldwide net revenues increased 10.2 percent on a reported basis, or 9.5 percent on an operational basis.
- The immunology portfolio increased 15.1 percent on a reported basis, driven by Skyrizi and Rinvoq growth.
- The neuroscience portfolio increased 20.3 percent on a reported basis.
- The proposed Apogee acquisition is expected to close in the third quarter of 2026 and has a total equity value of approximately $10.9 billion.
- FDA and EC approvals expanded Skyrizi and Rinvoq indications, while additional approvals and authorizations were reported across Aquipta, Decnupaz, Venclyxto and Tepkinly.
Concerns
- Humira global net revenues decreased 35.9 percent on a reported basis.
- The oncology portfolio decreased 1.5 percent on a reported basis, including a 29.4 percent decline for Imbruvica.
- Aesthetics portfolio revenue increased 0.3 percent on a reported basis and decreased 0.9 percent on an operational basis.
- Second-quarter results included an unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense.
- Updated 2026 adjusted diluted EPS guidance includes a $0.14 per Share dilutive impact related to the proposed acquisition of Apogee Therapeutics.
What to watch
- Execution and closing of the proposed Apogee Therapeutics acquisition in the third quarter of 2026.
- Skyrizi and Rinvoq growth relative to continuing Humira erosion.
- Whether Venclexta and Elahere growth can offset the reported Imbruvica decline in oncology.
- Whether Botox Cosmetic growth and Juvederm trends improve the aesthetics portfolio's operational performance.
- The acquired IPR&D and milestones expense impact included in 2026 adjusted diluted EPS guidance.
Balance sheet and cash flow
- Net interest expense was $679 million.
Analysis
AbbVie reported $16.990 billion of worldwide net revenues, up 10.2 percent on a reported basis and 9.5 percent on an operational basis. Adjusted diluted EPS was $3.65, up 22.9 percent, while GAAP diluted EPS was $2.03, up 290.4 percent. The company said quarterly EPS included an unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense.
Immunology remained the central growth engine, with $8.786 billion in portfolio revenue and 15.1 percent reported growth. Skyrizi generated $5.505 billion and Rinvoq generated $2.525 billion, with both products growing more than 24 percent on a reported basis. This growth was set against a $756 million Humira franchise that declined 35.9 percent on a reported basis.
Neuroscience produced $3.228 billion, up 20.3 percent on a reported basis, supported by Vraylar, Botox Therapeutic, Ubrelvy and Qulipta. Oncology revenue was $1.650 billion, down 1.5 percent on a reported basis as Venclexta and Elahere growth did not offset a 29.4 percent Imbruvica decline. Aesthetics was essentially flat at $1.282 billion, increasing 0.3 percent on a reported basis but decreasing 0.9 percent operationally, with Juvederm declining.
Profitability metrics showed a 74.7 percent GAAP gross margin ratio and an 84.7 percent adjusted gross margin ratio. GAAP operating margin was 37.9 percent and adjusted operating margin was 48.3 percent. GAAP R&D expense was 13.8 percent of net revenues, adjusted R&D expense was 13.6 percent, and acquired IPR&D and milestones expense was 1.7 percent of net revenues.
AbbVie updated its 2026 adjusted diluted EPS guidance range to $13.87 - $14.07. The company said the range includes a $0.14 per Share dilutive impact from the proposed Apogee Therapeutics acquisition, expected to close in the third quarter of 2026, and an unfavorable $0.58 Per Share impact from acquired IPR&D and milestones expense incurred year-to-date through the second quarter. The stated approximately $10.9 billion total equity value of Apogee makes transaction execution and the prospective contribution of its immunology pipeline key areas of focus.
Management, verbatim
AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value.
Robert A. Michael, chairman and chief executive officer, AbbVie
Not in the filing
stated, not guessed- Net income was not reported in the provided filing text.
- GAAP and non-GAAP operating income amounts were not reported in the provided filing text.
- Prior-year absolute values for worldwide net revenues, portfolio revenue, product revenue, EPS, margins, expenses, net interest expense and tax rates were not reported on their respective lines.
- Prior-quarter values and quarter-over-quarter changes were not reported.
- Operating cash flow was not reported in the provided filing text.
- Free cash flow was not reported in the provided filing text.
- Cash and cash equivalents were not reported in the provided filing text.
- Debt balances were not reported in the provided filing text.
- Share repurchases, dividends and other capital-return figures were not reported in the provided filing text.
- Revenue, gross-margin, operating-expense and tax-rate guidance were not reported in the provided filing text.
- A previous-release outlook was not provided; therefore, no comparison of reported results with prior guidance is included.
- The filing text was truncated after the Recent Events section; metrics or disclosures outside the provided text could not be assessed.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K for AbbVie’s Q2 2026 results (Item 2.02) with an attached press release and a disclosed definitive acquisition agreement for Apogee Therapeutics.
Ticker impact
AbbVie reported Q2 2026 results and updated 2026 adjusted EPS guidance, while also announcing a definitive deal to acquire Apogee Therapeutics.
Bias toward upside if investors view immunology growth and the guidance update as supportive, but expect volatility around acquisition-related dilution and integration assumptions.
The filing discloses concrete, decision-relevant numbers: Q2 GAAP and adjusted EPS, revenue by portfolio, and a specific guidance range change that explicitly includes acquisition-related dilution, plus deal terms and an expected Q3 2026 close.
Market effects
Reinforces large-cap pharma focus on immunology expansion and late-stage pipeline build via acquisitions; may influence read-through sentiment for IL-13/TSLP competitive landscape.
Primarily US-listed large-cap pharma sentiment; limited direct regional spillover beyond healthcare equities.
Global revenue growth and constant-currency framing may affect broader pharma earnings expectations and M&A appetite internationally.
Counterpoint
Immunology growth may not fully offset the decline in Humira, and the guidance update includes explicit dilutive impact, which could cap near-term multiple expansion.
Key entities
- issuerAbbVie Inc.
Reported Q2 2026 financial results and updated 2026 adjusted EPS guidance; announced acquisition of Apogee Therapeutics.
- acquisition_targetApogee Therapeutics
Definitive agreement target; contributes late-stage IL-13 and IL-13/TSLP pipeline assets; expected to close in Q3 2026.
- regulatorFDA
Mentioned in the filing as part of recent events, though the provided excerpt cuts off before details.
